Find the PSMA antibody that fits your needs. Choose from 1 of 63 PSMA antibodies, which have been validated in experiments with 11 publications and 178 images featured in our data gallery. Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications. Antibodies with...

Prostate specific membrane antigen (PSMA, also known as FOLH1), a type II transmembrane protein of the M28 family, has both folate hydrolase and N-acetylated-alpha-linked acidic dipeptidase activity.

Jul 4, 2022 · Whole-body (WB) MRI has been shown to have a high diagnostic performance in the detection and monitoring of metastatic bone disease. Prospective, randomized, multicentre studies comparing 68...

Prostate Specific Membrane Antigen (D7I8E) XP ® Rabbit mAb (BSA and Azide Free) recognizes endogenous levels of total prostate specific membrane antigen. An SDS resistant dimer at approximately 200 kDa can be detected depending on …

Oct 21, 2021 · Prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) outperform standard imaging technology for the detection of metastasis in prostate cancer (PCa).

Polyclonal Antibody for studying PSMA2. Validated for IF, WB. Highly specific and rigorously validated in-house, PSMA2 Antibody (CST #2455) is ready to ship.

Oct 21, 2021 · PSMA PET-CT and WB-MRI outperform standard imaging technology for staging high-risk prostate cancer, but direct comparison between both modalities is lacking.

Choose from 1 of 63 PSMA antibodies, which have been validated in experiments with 11 publications and 178 images featured in our data gallery. Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications.

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has emerged as a highly sensitive imaging modality for prostate cancer (PCa), outperforming conventional methods like CT, MRI, and bone scintigraphy.

Apr 15, 2023 · In this study, we employ dynamic whole-body (D-WB) PET imaging to compare the pharmacokinetics of [68 Ga]Ga-PSMA-11 and [18 F]PSMA-1007 in various tissues and lesions, and to assess whether Patlak parametric images are quantitative and improve lesion detection and image readability.